Quantitative analysis for Karyopharm Therapeutics Inc. (KPTI) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Strong Sell (26.0) (grade F). 27 signals analyzed (22 differentiated alt-data).
KPTI stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $8.59 | $8.11 | $8.40 |
| 2026-05-11 | $9.27 | $8.45 | $8.81 |
| 2026-05-21 | $8.24 | $7.72 | $8.06 |
| 2026-06-03 | $9.09 | $8.48 | $9.00 |
| 2026-06-15 | $9.80 | $9.36 | $9.64 |
| 2026-06-26 | $10.25 | $9.43 | $10.21 |
| 2026-07-09 | $10.76 | $10.09 | $10.20 |
| 2026-07-21 | $8.27 | $7.46 | $7.86 |
| 2026-07-31 | $2.43 | $1.80 | $1.92 |
| 2026-08-12 | $2.15 | $2.00 | $2.03 |
| 2026-08-24 | $1.96 | $1.83 | $1.86 |
| 2026-09-03 | $1.81 | $1.72 | $1.77 |
How Karyopharm Therapeutics Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| IMMP | Immutep Limited | $69M | — |
| LIXT | Lixte Biotechnology Holdings, Inc. | $69M | — |
| GUTS | Fractyl Health, Inc. Common Stock | $67M | — |
| SGMO | Sangamo Therapeutics, Inc. | $66M | — |
View all Health Care stocks by valuation and signals →
Karyopharm Therapeutics Inc. (KPTI) scores Strong Sell (26.0), and the composite conceals a 89-point disagreement between its dimensions. It is strongest on analyst consensus at 90, and weakest on technicals at 2 and competitive moat at 1. A stock can carry analyst consensus that high while competitive moat sits at 1; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 90 |
| technicals | 2 |
| competitive moat | 1 |
StoQuant analyzes 27 signals (22 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Karyopharm Therapeutics Inc. (KPTI): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/KPTI"><img src="https://stoquant.com/badge/KPTI.svg" alt="Karyopharm Therapeutics Inc. (KPTI) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.